Aardvark Therapeutics Inc

CUSIP 002942100COMAARDQ1 2026

13D / 13G Filings

Schedule 13D/13G on record

Beneficial Filers

Distinct reporting persons

Largest Stake

18.3%

Max % of class reported

Institutional Holders

13F filers (latest quarter)

4 filings · latest May 15, 2025

#	Filed	Reporting Person	Form	% of Class	Shares	Filing
1	May 15, 2025	Tien-Li Lee	13G	13.7%	2.98M	SEC
2	Feb 24, 2025	Decheng Capital Global Life Sciences Fund IV, L.P.	13G	18.3%	3.92M	SEC
3	Feb 24, 2025	Dr. Finian Tan	13G	9.6%	2.05M	SEC
4	Feb 24, 2025	Citadel Advisors LLC	13G	5.6%	1.19M	SEC

Largest reported positions · latest quarter

#	Fund	Shares	Value
1	Decheng Capital LLC	3.92M	$14.77M
2	Citadel Advisors LLC	1.24M	$4.69M
3	Laurion Capital Management LP	1.03M	$3.90M
4	Blackrock, Inc.	792.6K	$2.99M
5	Tetragon Partners Gp Ltd	316.6K	$1.19M
6	Geode Capital Management, LLC	309.4K	$1.17M
7	Adage Capital Partners Gp, L.L.C.	300.0K	$1.13M
8	State Street Corp	199.3K	$751.4K
9	Two Sigma Investments, LP	163.4K	$615.8K
10	Ubs Group AG	157.9K	$595.2K